In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Motus Gi Holdings (MOTS), with a price target of $2.00. The company’s shares closed last Thursday at $0.92, close to its 52-week low of $0.68.
According to TipRanks.com, Chen is a top 100 analyst with an average return of 55.7% and a 46.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Motus Gi Holdings with a $2.31 average price target, implying a 133.3% upside from current levels. In a report issued on April 30, Colliers Securities also reiterated a Buy rating on the stock with a $2.50 price target.
See today’s analyst top recommended stocks >>
Motus Gi Holdings’ market cap is currently $43.03M and has a P/E ratio of -1.60. The company has a Price to Book ratio of 4.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.
